Reproductive Endocrinology and Advanced Fertility Preservation
As the average age of first-time mothers continues to rise globally, the 2026 fertility drug market has expanded to include sophisticated ovarian protection and preservation agents
. Beyond standard gonadotropins (FSH and LH) used in IVF, new pharmacological strategies focus on "mitochondrial rescue" in oocytes to improve egg quality in older patients. Furthermore, for women undergoing chemotherapy, the use of GnRH agonists as temporary ovarian "suppressors" has become a standardized protocol to protect the primordial follicle pool from cytotoxic damage. The field is also seeing the rise of biosimilars for follicle-stimulating hormones, which has significantly lowered the cost of assisted reproductive technology (ART), making high-tier fertility treatments accessible to a broader demographic than ever before.